Detection of nucleic acids by target-specific hybrid capture method

• US 8,557,973 B2
• Filed: 10/14/2010
• Issued: 10/15/2013
• Est. Priority Date: 06/15/2000
• Status: Expired due to Fees

• Current Assignee: QIAGEN Gaithersburg, Inc. (Qiagen NV)
• Original Assignee: QIAGEN Gaithersburg, Inc. (Qiagen NV)
• Inventors: Anthony, James, Lorincz, Attila, Troy, John, Tan, Yanglin
• Primary Examiner(s): Chunduru, Prabha
• Application Number:
  US12/904,459
• Publication Number:
  US 20110059542A1
• Time in Patent Office: 1,097 Days
• Field of Search: None
• US Class Current: 536/24.3
• CPC Class Codes: C12Q 1/6832 Enhancement of hybridisation reaction
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/705 for herpetoviridae, e.g. herpes simplex, varicella zoster
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2525/186 incorporating a non-extendable or blocking moiety
• CPC Class Codes: C12Q 2565/519 characterised by the capture moiety being a single stranded oligonucleotide
• CPC Class Codes: C12Q 2565/543 characterised by the use of two or more capture oligonucleotide primers in concert, e.g. bridge amplification
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA-RNA hybrids which can be detected by a variety of methods.

Claims

1. An isolated nucleic acid probe:

(a) having an overall length of 100 nucleotides or less;

(b) comprising a first nucleotide sequence selected from the group consisting of SEQ ID NO;

75 to SEQ ID NO;

78, a full length complement thereof, and an RNA equivalent thereof; and

(c) capable of hybridizing to a Human papillomavirus type 16 (HPV

     16) nucleic acid under moderately stringent hybridization conditions.

2. The nucleic acid probe of claim 1 having an overall length of 40 nucleotides or less.

3. The nucleic acid probe of claim 1 consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO:

75 to SEQ ID NO;

78, a full-length complement thereof, and an RNA equivalent thereof.

4. The nucleic acid probe of claim 1, wherein the nucleic acid probe is modified with at least one ligand.

5. The nucleic acid probe of claim 4, wherein the ligand is selected from the group consisting of biotin, digoxigenin, and 2,4-dinitrophenol.

6. The nucleic acid probe of claim 4, wherein the nucleic acid probe is linear having a 5′

and 3′

end, wherein both the 5′ and

the 3′

ends are modified with a ligand.

7. The nucleic acid probe of claim 6, wherein the ligand at the 5′

and the 3′

ends is biotin.

8. The nucleic acid probe of claim 1, wherein the nucleic acid probe is modified with at least one fluorogen.

9. The nucleic acid probe of claim 8, wherein the fluorogen is selected from the group consisting of fluorescein and derivatives thereof, phycoerythrin, allo-phycocyanin, phycocyanin, rhodamine, and Texas Red.

10. The nucleic acid probe of claim 1 further comprising:

(d) a second nucleotide sequence at least 75% identical to a sequence selected from the group consisting of SEQ ID NO;

1 through SEQ ID;

29, SEQ ID NO;

50 through SEQ ID NO;

62, SEQ ID NO;

75 through SEQ ID NO;

109, and SEQ ID NO;

152 through SEQ ID NO;

154, a full length complement thereof, and an RNA equivalent thereof,

wherein the first and second nucleotide sequences are capable of hybridizing either to different regions of the same HPV 16 nucleic acid or to different viral nucleic acids.

11. The nucleic acid probe of claim 10, wherein the first and second nucleotide sequences are capable of hybridizing to different regions of the same HPV 16 nucleic acid and wherein said different regions are 3 kilobases or less apart.

12. The nucleic acid probe of claim 10, wherein the first and second nucleotide sequences are capable of hybridizing to different regions of the same HPV 16 nucleic acid and wherein said different regions are 500 bases or less apart.

13. The nucleic acid probe of claim 1 comprising:

a single stranded region comprising the first nucleotide sequence; and

a region comprising a DNA-RNA duplex.

14. The nucleic acid probe of claim 13, wherein the DNA-RNA duplex is an M13 DNA-M13 RNA duplex.

15. The nucleic acid probe of claim 1 further comprising a region capable of hybridizing to a poly(A) tail or a poly(dT) tail under moderately stringent hybridization conditions.

16. The nucleic acid probe of claim 1 further comprising a region capable of hybridizing to a second nucleic acid probe under moderately stringent hybridization conditions.

17. The nucleic acid probe of claim 1, wherein said nucleic acid probe is DNA, RNA, or PNA.

18. A blocker probe capable of hybridizing to a nucleic acid probe of claim 1 under moderate stringency conditions, wherein said blocker probe comprises a first sequence at least 5 nucleotides in length, said first sequence sharing at least 75% identity over its entire length with a sequence selected from the group consisting of SEQ ID NO:

122 through SEQ ID NO;

129, or a full length complement thereof, and wherein said blocker probe is at least 75% complementary to the full length of the nucleic acid probe.

19. The blocker probe of claim 18 wherein said blocker probe has a predicted melting temperature at least 10°

C. lower than the predicted melting temperature of the nucleic acid probe.

20. The blocker probe of claim 18 wherein said blocker probe comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:

122 through SEQ ID NO;

129, or a full length complement thereof.

21. The blocker probe of claim 18 wherein said blocker probe consists of a nucleotide sequence selected from the group consisting of SEQ ID NO:

122 through SEQ ID NO;

129 or a full length complement thereof.

22. The blocker probe of claim 18 wherein said blocker probe is at least 12 nucleotides in length.

23. The blocker probe of claim 18 wherein said blocker probe is 100% complementary to the full length of the nucleic acid probe.

24. A kit for detecting HPV 16, said kit comprising:

(a) at least one capture sequence probe, capable of hybridizing to a first region of an HPV 16 nucleic acid, wherein said capture sequence probe is bound to a solid phase or adapted to be bound to a solid phase;

(b) at least one blocker sequence probe capable of hybridizing to the capture sequence probe; and

(c) at least one signal sequence probe capable of hybridizing to a second region of the HPV 16 nucleic acid, wherein the signal sequence probe does not hybridize to the capture sequence probe and wherein the second region of the HPV 16 nucleic acid does not overlap with the first region of the HPV 16 nucleic acid and wherein the distance between the second region of the HPV 16 nucleic acid and the first region of the HPV 16 nucleic acid is 1000 bases or less;

wherein the capture sequence probe and/or the signal sequence probe is a nucleic acid probe of claim 1.

25. The kit of claim 24 further comprising a solid phase.

26. The kit of claim 24 wherein said signal sequence probe is detectably labeled.

27. A kit for detecting an HPV 16 nucleic acid, said kit comprising:

(a) at least one capture sequence probe capable of hybridizing to an HPV 16 nucleic acid, wherein said capture sequence probe is bound to a solid phase or adapted to be bound to a solid phase;

(b) at least one blocker sequence probe capable of hybridizing to the capture sequence probe;

(c) at least one bridge probe comprising a first sequence capable of hybridizing to a second region of the HPV 16 nucleic acid; and

(d) at least one signal sequence probe capable of hybridizing to the bridge probe and not capable of hybridizing to the HPV 16 nucleic acid;

wherein the capture sequence probe and/or the bridge probe is a nucleic acid probe of claim 1.

28. The kit of claim 27 further comprising a solid phase.

29. The kit of claim 27 wherein said signal sequence probe is detectably labeled.

30. The nucleic acid probe of claim 1, with the proviso that the nucleic acid probe does not contain any stretches of sequence homology to other HPV types greater than 12 bases.

31. The kit of claim 24, with the proviso that the capture sequence probe does not contain any stretches of sequence homology to other HPV types greater than 12 bases and is of sufficient length so as to be capable of hybridizing efficiently at 70°

C.